Patents by Inventor Masaya Kokubo
Masaya Kokubo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240079742Abstract: A battery includes a current collecting member connected to a power generating element housed in an outer casing with a lid, and a rivet placed outside the outer casing. The current collecting member includes a plate-shaped portion placed along the lid. The rivet includes a through part extending through the lid, and a contact part contacting a first surface of the plate-shaped portion. A part of a peripheral end portion of the contact part is joined to the first surface. An edge portion of a non-joined portion of the peripheral end portion, facing the first surface, includes a tapered surface generating a gap smaller at a position closer to the through part. The tapered surface has a maximum size of 0.1 mm or more in a direction from the peripheral end portion to the through part and 0.03 mm or more in a thickness direction of the peripheral end portion.Type: ApplicationFiled: August 15, 2023Publication date: March 7, 2024Applicants: PRIMEARTH EV ENERGY CO., LTD., TOYOTA JIDOSHA KABUSHIKI KAISHA, PRIME PLANET ENERGY & SOLUTIONS, INC.Inventors: Keitaro MACHIDA, Masaya OGURA, Akinori KOKUBO, Yuya TANAKA, Koichi TANIMOTO
-
Patent number: 11919917Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.Type: GrantFiled: August 6, 2021Date of Patent: March 5, 2024Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Ryosuke Hanada, Masaya Kokubo, Masakuni Kurono, Kenichi Kouda, Hiroshi Hagiya
-
Publication number: 20230339992Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.Type: ApplicationFiled: June 22, 2023Publication date: October 26, 2023Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Ryosuke HANADA, Masaya KOKUBO, Masakuni KURONO, Kenichi KOUDA, Hiroshi HAGIYA
-
Publication number: 20230151024Abstract: The object of the present invention is to provide a drug containing a compound having an agonistic activity to STING as an active ingredient. As a result of intensive studies by the inventors of the present invention, the compound represented by the following general formula (I-1) [in the formula, all symbols represent the same meanings as described in the present specification.] or the like, having the agonistic activity to STING, as a substance capable of solving such objects, and this invention was completed. Since the compound represented by the general formula (I-1) or the like of the present invention has the agonistic activity to STING, it can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.Type: ApplicationFiled: April 10, 2020Publication date: May 18, 2023Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Ryosuke HANADA, Masaya KOKUBO, Masakuni KURONO, Kenichi KOUDA, Hiroshi HAGIYA
-
Publication number: 20210363166Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.Type: ApplicationFiled: August 6, 2021Publication date: November 25, 2021Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Ryosuke HANADA, Masaya KOKUBO, Masakuni KURONO, Kenichi KOUDA, Hiroshi HAGIYA
-
Patent number: 11130773Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.Type: GrantFiled: October 10, 2019Date of Patent: September 28, 2021Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Ryosuke Hanada, Masaya Kokubo, Masakuni Kurono, Kenichi Kouda, Hiroshi Hagiya
-
Publication number: 20210253615Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.Type: ApplicationFiled: October 10, 2019Publication date: August 19, 2021Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Ryosuke HANADA, Masaya KOKUBO, Masakuni KURONO, Kenichi KOUDA, Hiroshi HAGIYA
-
Patent number: 10886867Abstract: An inverter control device that controls an inverter as a control target, the inverter being connected to a direct-current power supply and connected to an alternating-current rotating electrical machine so as to convert power between direct current and alternating current of a plurality of phases, and the inverter having an arm for each alternating-current phase, the arm including a series circuit of an upper-stage switching element and a lower-stage switching element, the inverter control device including an electronic control unit.Type: GrantFiled: September 29, 2017Date of Patent: January 5, 2021Assignee: AISIN AW CO., LTD.Inventors: Subrata Saha, Arinori Shimada, Yuki Sugiyama, Masaya Kokubo
-
Patent number: 10351002Abstract: An inverter control device that controls a rotary electric machine drive device that includes an inverter with a plurality of switching elements, where the active short circuit control is executed in a high rotational speed region, and the shut-down control is executed in a low rotational speed region, which is on a low rotational speed side with respect to the high rotational speed region, in accordance with at least a rotational speed of the rotary electric machine.Type: GrantFiled: November 13, 2015Date of Patent: July 16, 2019Assignee: AISIN AW CO., LTD.Inventors: Subrata Saha, Takashi Yoshida, Yuki Sugiyama, Yoichi Tajima, Masaya Kokubo
-
Publication number: 20190214933Abstract: An inverter control device that controls an inverter as a control target, the inverter being connected to a direct-current power supply and connected to an alternating-current rotating electrical machine so as to convert power between direct current and alternating current of a plurality of phases, and the inverter having an arm for each alternating-current phase, the arm including a series circuit of an upper-stage switching element and a lower-stage switching element, the inverter control device including an electronic control unit.Type: ApplicationFiled: September 29, 2017Publication date: July 11, 2019Applicant: AISIN AW CO., LTD.Inventors: Subrata SAHA, Arinori SHIMADA, Yuki SUGIYAMA, Masaya KOKUBO
-
Publication number: 20170305274Abstract: An inverter control device that controls a rotary electric machine drive device that includes an inverter with a plurality of switching elements, where the active short circuit control is executed in a high rotational speed region, and the shut-down control is executed in a low rotational speed region, which is on a low rotational speed side with respect to the high rotational speed region, in accordance with at least a rotational speed of the rotary electric machine.Type: ApplicationFiled: November 13, 2015Publication date: October 26, 2017Applicant: AISIN AW CO., LTD.Inventors: Subrata SAHA, Takashi YOSHIDA, Yuki SUGIYAMA, Yoichi TAJIMA, Masaya KOKUBO
-
Patent number: 8871210Abstract: The present invention relates to a compound represented by formula (I): wherein all symbols are as defined here, a salt thereof, a solvate thereof, or a prodrug thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.Type: GrantFiled: November 8, 2013Date of Patent: October 28, 2014Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Masaya Kokubo, Motoyuki Tanaka, Hiroshi Ochiai, Yoshikazu Takaoka, Shiro Shibayama
-
Patent number: 8822459Abstract: The present invention relates to a compound represented by formula (I-0): wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.Type: GrantFiled: February 15, 2011Date of Patent: September 2, 2014Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Masaya Kokubo, Yoshikazu Takaoka, Shiro Shibayama
-
Publication number: 20140187630Abstract: Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and/or therapeutic agent for Parkinson's disease and/or Parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa.Type: ApplicationFiled: March 5, 2014Publication date: July 3, 2014Applicant: ONO PHARMACEUTICALS CO., LTD.Inventors: Masaya KOKUBO, Koji YANO
-
Patent number: 8748485Abstract: Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and/or therapeutic agent for Parkinson's disease and/or Parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa.Type: GrantFiled: December 1, 2011Date of Patent: June 10, 2014Assignee: Ono Pharmaceuticals Co., Ltd.Inventors: Masaya Kokubo, Koji Yano
-
Patent number: 8703816Abstract: Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and/or therapeutic agent for Parkinson's disease and/or Parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa.Type: GrantFiled: December 1, 2011Date of Patent: April 22, 2014Assignee: Ono Pharmaceuticals Co., Ltd.Inventors: Masaya Kokubo, Koji Yano
-
Publication number: 20140072576Abstract: The present invention relates to a compound represented by formula (I): wherein all symbols are as defined here, a salt thereof, a solvate thereof, or a prodrug thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.Type: ApplicationFiled: November 8, 2013Publication date: March 13, 2014Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Masaya KOKUBO, Motoyuki TANAKA, Hiroshi OCHIAI, Yoshikazu TAKAOKA, Shiro SHIBAYAMA
-
Patent number: 8618122Abstract: A compound represented by general formula (I): a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification. The compound of the present invention has antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.Type: GrantFiled: May 15, 2007Date of Patent: December 31, 2013Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Kensuke Kusumi, Masaya Kokubo, Hiroshi Ochiai, Shiro Shibayama
-
Patent number: 8614323Abstract: The present invention relates to a compound represented by formula (I): wherein all symbols are as defined here, a salt thereof, a solvate thereof, or a prodrug thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.Type: GrantFiled: August 28, 2012Date of Patent: December 24, 2013Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Masaya Kokubo, Motoyuki Tanaka, Hiroshi Ochiai, Yoshikazu Takaoka, Shiro Shibayama
-
Publication number: 20130245074Abstract: Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and/or therapeutic agent for Parkinson's disease and/or Parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa.Type: ApplicationFiled: December 1, 2011Publication date: September 19, 2013Applicant: ONO PHARMACEUTICALS CO., LTD.Inventors: Masaya Kokubo, Koji Yano